CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T c...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2022-06-01
|
| Sarja: | Frontiers in Immunology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.927153/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|